Rhodopsin (RHO) (C-Term) Antikörper

Antigen: Rhodopsin (RHO)

Synonyme: RP4, OPN2, CSNBAD1, MGC138309, MGC138311, Rh, RH1, zfo2, zfrho, fi06d11, wu:fi06d11, CG5279, Dm Rh5, DMELRH5, DmelCG5279, rh5, RH5, DMELRH4, Dm Rh4, FBgn0003250, RH4, DmelCG9668, CG9668, CG5192, Dm Rh6, DMELRH6, DmelCG5192, R8, rh6, RH6, 143283_at, 1F9, BEST:GH11778, DMELRH1, Dm Rh1, DmRh1, FBgn0002940, Nina E, R, Rh1/ninaE, opsin, ora, rhodopsin, DmelCG4550, CG4550, DMELRH3, Dm Rh3, FBgn0003249, RH3, DmelCG10888, CG10888, Ops, Opn2, Noerg1, MGC21585, MGC25387, rho, MGC64248, PRA1, CHK-1, RHO, PIGRHO1, ops, RDP1, rp4, opn2, xrho, kfh-rh

Epitope: C-Term

Klonalität: Polyklonal

Wirt: Kaninchen

Applikation: Immunhistochemie (IHC), Western Blot (WB)

Produktnummer: ABIN350797

Produktbeschreibung

Weitere Bezeichnung: Rhodopsin (OPSD, Opsin-2) (c-terminal region)

Swiss-Prot: P08100

Immunogen: A synthetic peptide from human Rhodopsin (OPSD, opsin-2, RHO, OPN2, RP4) conjugated to an immunogenic carrier protein was used as the immunogen. The antigen is homologous in mouse and rat.

Format: Lyophilized

Beschreibung: FUNCTION: Photoreceptor required for image-forming vision at low light intensity. Required for photoreceptor cell viability after birth. Light-induced isomerization of 11-cis to all-trans retinal triggers a conformational change leading to G-protein activation and release of all-trans retinal. BIOPHYSICOCHEMICAL PROPERTIES: Absorption:       Abs(max)=495 nm; SUBCELLULAR LOCATION: Membrane; Multi-pass membrane protein. TISSUE SPECIFICITY: Rod shaped photoreceptor cells which mediates vision in dim light. PTM: Phosphorylated on some or all of the serine and threonine residues present in the C-terminal region. DISEASE: Defects in RHO are the cause of retinitis pigmentosa type 4 (RP4). RP leads to degeneration of retinal photoreceptor cells. Patients typically have night vision blindness and loss of midperipheral visual field. As their condition progresses, they lose their far peripheral visual field and eventually central vision as well. RP4 inheritance is autosomal dominant. DISEASE: Defects in RHO are a cause of retinitis pigmentosa autosomal recessive (ARRP). DISEASE: Defects in RHO are a cause of autosomal dominant congenital stationary night blindness 1 (CSNBAD1); also known as rhodopsin-related congenital stationary night blindness. Congenital stationary night blindness is a nonprogressive retinal disorder characterized by impaired night vision and ocular symptoms such as myopia, hyperopia, nystagmus and reduced visual acuity. Also known as: Rhodopsin, opsin-2, RHO, OPN2, RP4, MGC138309, MGC138311.

Spezifität: Appears to be specific for Rhodopsin.

Synonyme: RP4, OPN2, CSNBAD1, MGC138309, MGC138311, Rh, RH1, zfo2, zfrho, fi06d11, wu:fi06d11, CG5279, Dm Rh5, DMELRH5, DmelCG5279, rh5, RH5, DMELRH4, Dm Rh4, FBgn0003250, RH4, DmelCG9668, CG9668, CG5192, Dm Rh6, DMELRH6, DmelCG5192, R8, rh6, RH6, 143283_at, 1F9, BEST:GH11778, DMELRH1, Dm Rh1, DmRh1, FBgn0002940, Nina E, R, Rh1/ninaE, opsin, ora, rhodopsin, DmelCG4550, CG4550, DMELRH3, Dm Rh3, FBgn0003249, RH3, DmelCG10888, CG10888, Ops, Opn2, Noerg1, MGC21585, MGC25387, rho, MGC64248, PRA1, CHK-1, RHO, PIGRHO1, ops, RDP1, rp4, opn2, xrho, kfh-rh

Anwendungen

Applikationshinweise: IHC, WB. A dilution of 1 : 300 to 1 : 2000 is recommended. The optimal dilution should be determined by the end user. Not yet tested in other applications.

Reinheit: whole serum

Lagerung: Maintain the lyophilised/reconstituted antibodies frozen at -20°C for long term storage and refrigerated at 2-8°C for a shorter term. When reconstituting, glycerol (1:1) may be added for an additional stability. Avoid freeze and thaw cycles.

Beschränkungen: Nur für Forschungszwecke einsetzbar

Publikationen

Publikationen: Farrar, Findlay, Kumar-Singh et al.: "Autosomal dominant retinitis pigmentosa: a novel mutation in the rhodopsin gene in the original 3q linked family." in: Human molecular genetics, Vol. 1, Issue 9, pp. 769-71, 1993 (PubMed).

Sung, Davenport, Hennessey et al.: "Rhodopsin mutations in autosomal dominant retinitis pigmentosa." in: Proceedings of the National Academy of Sciences of the United States of America, Vol. 88, Issue 15, pp. 6481-5, 1991 (PubMed).

Dryja, McGee, Reichel et al.: "A point mutation of the rhodopsin gene in one form of retinitis pigmentosa." in: Nature, Vol. 343, Issue 6256, pp. 364-6, 1990 (PubMed).

Nathans, Hogness: "Isolation and nucleotide sequence of the gene encoding human rhodopsin." in: Proceedings of the National Academy of Sciences of the United States of America, Vol. 81, Issue 15, pp. 4851-5, 1984 (PubMed).

Macke, Hennessey, Nathans: "Rhodopsin mutation proline347-to-alanine in a family with autosomal dominant retinitis pigmentosa indicates an important role for proline at position 347." in: Human molecular genetics, Vol. 4, Issue 4, pp. 775-6, 1995 (PubMed).

Sieving, Richards, Naarendorp et al.: "Dark-light: model for nightblindness from the human rhodopsin Gly-90-->Asp mutation." in: Proceedings of the National Academy of Sciences of the United States of America, Vol. 92, Issue 3, pp. 880-4, 1995 (PubMed).

Vaithinathan, Berson, Dryja: "Further screening of the rhodopsin gene in patients with autosomal dominant retinitis pigmentosa." in: Genomics, Vol. 21, Issue 2, pp. 461-3, 1994 (PubMed).

Macke, Davenport, Jacobson et al.: "Identification of novel rhodopsin mutations responsible for retinitis pigmentosa: implications for the structure and function of rhodopsin." in: American journal of human genetics, Vol. 53, Issue 1, pp. 80-9, 1993 (PubMed).

Bennett, Sun, Karikuo: "Sequence analysis of the 5.34-kb 5' flanking region of the human rhodopsin-encoding gene." in: Gene, Vol. 167, Issue 1-2, pp. 317-20, 1996 (PubMed).

Lee, Shin, Cho et al.: "Detection of vivax malaria sporozoites naturally infected in Anopheline mosquitoes from endemic areas of northern parts of Gyeonggi-do (Province) in Korea." in: The Korean journal of parasitology, Vol. 40, Issue 2, pp. 75-81, 2002 (PubMed).